Genetic Signatures latest Investor Presentation released. Click link for more information.

Genetic Signatures latest Investor Presentation released. Click link for more information.

Genetic Signatures latest Investor Presentation released. Click link for more information.

A recent article published in Australia’s Sydney Morning Herald with Genetic Signatures’ CEO Dr. John Melki discusses how our novel 3baseTM technology utilised in our EasyScreenTM SARS-CoV-2 Detection Kit has assisted in the quick diagnosis of the virus amongst patients. For more on the article click link “It is ultimately saving lives’: Businesses respond to…

A recent article published in Australia’s Sydney Morning Herald highlights the importance of nationwide screening for COVID-19 testing. For more on the article click link Inside a COVID-19 lab and why more people return inconclusive tests    

Genetic Signatures are pleased to advise that our EasyScreenTM SARS-CoV-2 Detection Kit (the virus that causes COVID-19) has been registered for inclusion in the Australian Register of Therapeutic Goods (ARTG). To view the ASX announcement click here

Genetic Signatures are pleased to advise that our application for CE-IVD registration of our EasyScreen™ SARS-CoV-2 Detection Kit was granted overnight (Tuesday 31st March 2020). This allows the kit to be marketed freely in the European Union, and the customers whose kits were already shipped to Europe can start testing once they have finished setting…

Genetic Signatures are pleased to be attending the 6th Joint Conference of the DGHM & VAAM, which encompasses the German Society for Hygiene and Microbiology (DGHM) and the Association for General and Applied Microbiology (VAAM). This will be held in Leipzig (Germany) from 08–11 March 2020. The key topics are big data, microbial physiology and…

Genetic Signatures are pleased to be joining over 700 delegates at the prestigious 19. Klinisch-Mikrobiologisch-Infektiologisches Symposium held at Russisches Haus der Wissenschaft und Kultur in Berlin. “This year’s conference will focus on the topic “Responsible use of diagnostics for the detection and therapy management of infectious diseases” and will for the first time include the…

Last week we were honoured with a visit from our Angel investor and co-founder Chris Abbott. His recent The Australian Financial Review interview alongside our CEO John Melki details his long term interest in Biotech, Molecular Diagnostics and Genetic signatures in particular. We have been lucky to have great investors and advisors to guide our…